Navigation Links
Pitt receives $11 million from NIH to coordinate hepatitis B clinical research network
Date:1/29/2009

PITTSBURGH, Jan. 29 The National Institute of Diabetes and Digestive and Kidney Diseases has awarded a seven-year $11 million grant to the University of Pittsburgh Graduate School of Public Health to coordinate the Hepatitis B Clinical Research Network a consortium of 15 clinical and research centers in the U.S. and Canada that will conduct translational research on hepatitis B.

The network will include a multi-site treatment trial, create and maintain a large database of study results and store tissue and serum samples to facilitate clinical and basic research.

Hepatitis B is an infection that affects the liver. About 1.5 million Americans and 350 million people worldwide have chronic hepatitis B infection, which can lead to more serious diseases such as cirrhosis, liver failure and liver cancer.

"Medical advances have led to many treatments for chronic hepatitis B infection and most patients respond to them," said Steven Belle, Ph.D., principal investigator of the data coordinating center and professor of epidemiology, University of Pittsburgh Graduate School of Public Health. "However, these treatments do not cure the infection, but contain it by making it more difficult for the virus to reproduce."

Many patients need to stay on therapy for a long time, he added. And when treatment is prolonged, the virus can become resistant, making further treatment ineffective.

"We don't know why treatment works better for some patients than others, and we cannot accurately predict who may go on to develop liver abnormalities," said Dr. Belle. "But with the interdisciplinary expertise within the network, we hope to learn more about the immune changes that occur with hepatitis B infection and make inroads to finding a lasting cure."


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1

Related medicine news :

1. ProAssurance Receives Regulatory Approvals for Transactions with the PICA Group and Georgia Lawyers Insurance Company
2. PEAK Surgical Receives European CE Mark for PEAK(R) Surgery System for Use in General Surgery
3. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
4. UTSA receives federal funding for fossil fuel research
5. ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica
6. UTSA receives $1.2 million gift from Kleberg Foundation
7. IPC The Hospitalist Company Receives Best IPO Award from Los Angeles Venture Association
8. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
9. YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof
10. CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy
11. MSU researcher receives $1.5 million grant for childhood obesity intervention study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... New York, New York (PRWEB) March 04, 2015 ... ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin drug caused ... forward in the U.S. District Court, District of South ... Conference will be convened on March 26, 2015 at ... have been directed to submit a Joint Status report ...
(Date:3/4/2015)... WV (PRWEB) March 04, 2015 TROY ... (TSPE) software, which provides the ultimate level of security ... at the Hilton Houston Plaza Medical Center located at ... , Beginning at 7 AM, TROY Healthcare Solutions ... TROY Healthcare Solutions will offer brief presentations each hour ...
(Date:3/4/2015)... FDA’s New Inspection Approach:, What Your Inspector ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... hours of an inspection whether a manufacturer’s in trouble ... list, they’ll merely ask for reassurance that they know ... “bad” list, the manufacturer must get ready to convince ...
(Date:3/4/2015)... March 04, 2015 Cook For Your ... that teaches healthy cooking to people touched by cancer, ... Lodge. The program, run by founder Ann Ogden, will ... Sport Management. The unique partnership will expand the program ... founded CFYL in 2007. After going through her own ...
(Date:3/4/2015)... 2015 The ability of volumetric ... assessment and help improve breast cancer risk prediction ... for presentation at the European Congress of Radiology ... - eight posters and 2 session presentations - ... density and quantitative breast imaging software tools to ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5
... care plans share some important elements, but Sen. ... result in higher overall health care,spending than Sen. ... health policy researcher., Thorpe, professor of health ... Health, is the author of two analyses that ...
... least one disability, CDC says , , THURSDAY, Oct. 2 (HealthDay ... five people -- have some type of disability, according to ... a new CDC study finds that black, Hispanic and Native ... disproportionately higher rates than white or Asian Americans. , Overall, ...
... to Address Critical Issues During ... National Breast Cancer Awareness Month, DALLAS, Oct. 2 ... debate between vice presidential candidates Sen. Joe,Biden and Gov. Sarah ... Ifill reserve time for an issue that is both timely ...
... to Receive Full Benefits After Retirement, WASHINGTON, ... employer-sponsored retirement plans, retiree,medical plans or other financial ... Security or Medicare payments after they retire. Confidence ... female or have a,lower level of education, according ...
... Pa., Oct. 2 InnerLink, an innovative,developer of health ... company in Central Pennsylvania by the Central Penn Business,Journal. ... honors,businesses that have made significant contributions to the growth,strength, ... are honored to be recognized for our recent growth," ...
... AIDS in an unfiltered way that is both public ... this exploration may lead to another way to distribute ... associate professor of information sciences and technology (IST), an ... blog following an August 2006 ABC News story, "Out ...
Cached Medicine News:Health News:Emory Health Policy Expert Weighs in on Candidates' Health Care Plans 2Health News:Emory Health Policy Expert Weighs in on Candidates' Health Care Plans 3Health News:Minorities With Disabilities Report Poorer Health 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Suggests Questions for Vice Presidential Debate 2Health News:Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds 2Health News:Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds 3Health News:InnerLink Named Among Fastest Growing Companies in Central Pennsylvania 2Health News:African-American blogs offer key health communications tool 2Health News:African-American blogs offer key health communications tool 3
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
(Date:3/4/2015)... 2015  The strongest driver of demand in ... elderly population, according to Kalorama Information. The finding ... healthcare market research publisher, Global Orthopedic Device ... factors such as obesity is contributing to the ... product designs and the trend toward cost effective ...
(Date:3/4/2015)... China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or ... in China, today announced its financial results for the ... Fourth Quarter 2014 Financial Highlights , Total ... 36.2%, or 36.8% excluding the impact of foreign currency ... in the same quarter of 2013. , Gross ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22
... N.J., Sept. 28, 2011 Findings from an international Phase ... showed the device was safe and effective at restoring continence ... with a colostomy.  In addition, 87% of users rated the ... "very good," according to the study results published in the ...
... Edwards, Inc. (Nasdaq: MSHL ), an oncology ... targeting cancer metabolism, announced today that it has entered ... Limited, to sell common stock in a private placement ... and expenses of the offering, through the sale of ...
Cached Medicine Technology:Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 2Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 3Marshall Edwards Announces $2 Million Private Placement 2Marshall Edwards Announces $2 Million Private Placement 3
... Utilizing process automation, robust interfaces ... EMR/Practice Management), and rules-based technology, ... improves efficiency, reduces errors, and ... Harvest LIS includes many powerful, ...
... The Bio-Optics LSM-12000 is a new ... powerful new tool in anterior segment diagnostics ... easy to operate, easy to maintain, and ... is the only High Magnification Slit-Lamp Biomicroscope ...
... 28 Hue test studies the characteristic ... Farnsworth D15, however this 28 hue ... of sensitivity. Case comes with a ... readable. Kit includes laminated scoring template ...
This is a reduced form of the 100 Hue test and L'Anthony New Color Test. The 40 Hue test is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score...
Medicine Products: